Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Carboplatin 150mg/15ml injection

Ferron Par Pharmaceuticals

Ingredients in every 15 ml

Carboplatin 150 mg

Each package contains

1 vial of 15 ml

Dosage form

injection

Dosage formInjection

Flavour

None

W.H.O. classification

L01X
L01X

A.T.C. Level 1

Anatomical Main group

L - Antineoplastic and immunomodulating agents
L01X

A.T.C. Level 2

Therapeutic subgroup

L01 - Antineoplastic Agents
L01X

A.T.C. Level 3

Pharmacological subgroup

L01X - Other Antineoplastic Agents in ATC

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Advanced ovarian carcinoma
Small-Cell and Non-Small-Cell carcinoma of the lung
Squamous cell carcinoma of the head and neck
Advanced transitional cell carcinoma of the bladder
Carboplatin is frequently used in combination with other chemotherapeutic agent in various indications, such as with paclitaxel in first line therapy of ovarian carcinoma and Non-Small-Cell lung carcinoma. Significant responses have been observed when carboplatin employed in the treatment of carcinoma of the cervix.

Dosage

18 YEARS OLD AND ABOVE
The recommended dose of carboplatin in previously untreated adults patients with normal kidney is 400 mg/m² as a single intravenous infusion over 15-60 minutes. Therapy should not be repeated until four weeks after the previous carboplatin course and/or the neutrophil count is at least 2,000 cells/mm³ and the platelet count is at least 100,000 cells/mm³. It is recommended that according to clinical circumstances, the initial dosage may require reduction by 20-25% in patients with risk factors such as previous myelosuppressive therapy and poor performance status. Determination of hematological nadir by weekly blood counts during initial courses is recommended for future dosage adjustment and scheduling of carboplatin.

— Combination therapy
The optimal use of carboplatin in combination with other myelosuppressive agents requires dosage adjustments according to the regimen and schedule to be adopted.